#1 Clinical Trials Search in Europe

Fluticasone Propionate

This article summarizes several clinical trials investigating the use of fluticasone propionate, a corticosteroid medication, in treating asthma and allergic rhinitis. The studies examine various formulations and dosages of fluticasone propionate, comparing its effectiveness to other treatments and placebos in managing symptoms and improving lung function in both adults and children with these respiratory conditions.

Table of Contents

What is Fluticasone Propionate?

Fluticasone propionate is a medication that belongs to a class of drugs called inhaled corticosteroids. It is commonly used to treat respiratory conditions, particularly asthma[1]. This medication is known by several brand names, including Flovent Diskus®, Flixotide®, and Flixotide Evohaler[1][2].

What Conditions Does Fluticasone Propionate Treat?

Fluticasone propionate is primarily used to treat the following conditions:

  • Asthma: It is widely used for the management of mild to moderate persistent asthma in both adults and children[3].
  • Seasonal and Perennial Allergic Rhinitis: Some formulations of fluticasone propionate are used to treat allergies that occur seasonally or year-round[4].
  • COVID-19: Research is being conducted to evaluate its potential benefits in treating early-stage COVID-19[2].

How Does Fluticasone Propionate Work?

Fluticasone propionate works by reducing inflammation in the airways. When inhaled, it helps to decrease swelling and irritation in the lungs, making it easier to breathe. This anti-inflammatory effect helps prevent asthma symptoms and reduces the frequency and severity of asthma attacks[5].

How is Fluticasone Propionate Administered?

Fluticasone propionate is typically administered through inhalation. There are several ways it can be taken:

  • Metered-dose inhaler (MDI): A device that delivers a specific amount of medication in aerosol form[6].
  • Dry powder inhaler: A device that delivers the medication in a dry powder form, such as the Diskus® inhaler[1].
  • With a spacer: For young children or those who have difficulty using an inhaler, a spacer device with a face mask may be used[6].

The dosage and frequency of use can vary depending on the severity of the condition and the patient’s age. It’s important to follow your doctor’s instructions carefully.

Effectiveness of Fluticasone Propionate

Research has shown that fluticasone propionate is effective in managing asthma symptoms and improving lung function. Studies have demonstrated improvements in measures such as:

  • Forced Expiratory Volume in 1 second (FEV1): This is the amount of air a person can forcefully exhale in one second, which is often improved with fluticasone propionate use[1].
  • Peak Expiratory Flow Rate (PEFR): The maximum speed of exhalation, which tends to increase with treatment[1].
  • Asthma Control Days: Days when patients experience minimal to no asthma symptoms[1].

Potential Side Effects

While fluticasone propionate is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Throat irritation
  • Hoarseness
  • Oral thrush (a fungal infection in the mouth)

In rare cases, more serious side effects can occur. It’s important to discuss any concerns with your healthcare provider[6].

Ongoing Research

Researchers continue to study fluticasone propionate to understand its full potential and optimize its use. Some areas of ongoing research include:

  • Its effectiveness when combined with other medications, such as long-acting beta-agonists (LABAs) or leukotriene receptor antagonists (LTRAs)[1].
  • Its potential role in treating COVID-19 symptoms[2].
  • Its safety and efficacy in very young children (ages 1 to 4 years)[6].

As with any medication, it’s crucial to use fluticasone propionate under the guidance of a healthcare professional. They can provide personalized advice based on your specific health needs and monitor your response to the treatment.

Aspect Details
Conditions Studied Asthma, Allergic Rhinitis (Seasonal and Perennial)
Age Groups Children (1-11 years), Adolescents, Adults
Formulations Metered-Dose Inhalers, Dry Powder Inhalers, Nasal Sprays
Comparators Placebo, Other corticosteroids, Combination therapies (e.g., fluticasone/salmeterol)
Primary Outcomes Lung function (FEV1, PEFR), Symptom scores, Exacerbation rates, Safety profiles
Secondary Outcomes Quality of life, Individual symptom improvements, Pharmacokinetics
Study Designs Randomized controlled trials, Open-label studies, Crossover designs
Duration Varied from 2 weeks to 12 weeks, with some longer-term safety monitoring

FAQ

  • What conditions is fluticasone propionate used to treat in these clinical trials? Fluticasone propionate is primarily used to treat asthma and allergic rhinitis (hay fever) in the clinical trials discussed. It is studied in both adults and children with these respiratory conditions.
  • How is fluticasone propionate administered in these studies? Fluticasone propionate is administered in various forms across the studies, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nasal sprays. The specific formulation depends on whether it's being used for asthma or allergic rhinitis.
  • What are some of the primary outcomes measured in these trials? Primary outcomes often include changes in lung function (such as FEV1 for asthma), symptom scores, quality of life measures, and the frequency of exacerbations or adverse events. For allergic rhinitis, nasal symptom scores are commonly used.
  • Are there any studies comparing fluticasone propionate to other medications? Yes, several studies compare fluticasone propionate to other treatments. For example, some trials compare it to combination therapies like fluticasone propionate/salmeterol, while others compare different doses or formulations of fluticasone propionate itself.
  • What age groups are included in these clinical trials? The clinical trials cover a wide range of age groups. Some studies focus on children as young as 1-4 years old, while others include adolescents and adults. There are specific trials designed for pediatric populations and others for adult patients.

Ongoing Clinical Trials on Fluticasone Propionate

  • Study on the Effectiveness of Fluticasone Propionate and Amoxicillin-Clavulanic Acid for Children with Long-Lasting Cough

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Asthma in Patients Aged 12 and Older

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Poland Romania Slovakia

  • Study on the Effects of EP-104IAR and Tetracosactide for Adults with Eosinophilic Esophagitis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effects of Umeclidinium and Vilanterol in Patients with COPD and Heart Failure

    Recruiting

    3 1 1
    Investigated drugs:
    Spain

  • Study on Baclofen for Reducing Benzodiazepine Use in Patients with Benzodiazepine Dependence

    Recruiting

    4 1 1
    Investigated drugs:
    France

  • Study on Glycopyrronium Bromide for Children Aged 6-12 with Asthma

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Poland Spain

  • Study on the Effectiveness and Safety of Indacaterol Acetate/Mometasone Furoate vs. Budesonide for Children Aged 6-11 with Asthma

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Czechia Greece Hungary Italy +3

  • Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Hungary Poland Romania Slovakia +1

  • Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • Study of inhaled corticosteroids (beclometasone, fluticasone, budesonide) and salbutamol in children aged 1-6 years with episodic wheezing

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Fluticasone Propionate: A synthetic corticosteroid used as an anti-inflammatory medication to treat asthma and allergic rhinitis. It works by reducing inflammation in the airways.
  • Metered-Dose Inhaler (MDI): A device that delivers a specific amount of medication to the lungs in the form of a short burst of aerosolized medicine that is usually self-administered by the patient via inhalation.
  • Dry Powder Inhaler (DPI): An inhaler device that delivers medication to the lungs in the form of a dry powder, activated by the patient's inhalation.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the volume of air that can be forcibly exhaled in one second after taking a deep breath.
  • Peak Expiratory Flow Rate (PEFR): The maximum flow rate achieved during a forceful exhalation, used to measure airway obstruction.
  • Exacerbation: A worsening of symptoms or an acute episode in a chronic disease, such as asthma.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the active drug being tested.
  • Randomized Controlled Trial: A type of scientific experiment where participants are randomly allocated to receive either the treatment under investigation or a placebo/standard treatment, used to test the efficacy and safety of new interventions.
  • Allergic Rhinitis: Inflammation of the nasal passages caused by an allergic reaction, commonly known as hay fever.
  • Spacer: A device used with an inhaler to increase the ease of administering aerosolized medication and improve its delivery to the lungs.

References

  1. https://clinicaltrials.gov/study/NCT00395304
  2. https://clinicaltrials.gov/study/NCT05054322
  3. https://clinicaltrials.gov/study/NCT00441441
  4. https://clinicaltrials.gov/study/NCT06180083
  5. https://clinicaltrials.gov/study/NCT00995657
  6. https://clinicaltrials.gov/study/NCT03273946